Clinical Trial

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-08-18; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2024-03-11
Trial Details
NCT Number NCT06008288
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Enrollment 88 participants
Start Date 2023-10-27
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13